The results will be presented at the 15th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Sept. 16 to 19, and included in its press program. LOS ANGELES–(BUSINESS WIRE)–A study led by City of Hope, one of the largest cancer research and treatment organizations in the … [Read more…]
Company Introduces New Long-Term Financial Goals PLYMOUTH MEETING, Pa.–(BUSINESS WIRE)–AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, will host and webcast its 2022 Capital Markets Day beginning at 9:00 a.m. ET today. During the event, Chief Executive Officer … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “U.S. Behavioral Health EHR Market Size, Share & Trends Analysis Report by End Use (State-owned, Private), and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering. The U.S. behavioral health EHR market size is expected to reach USD 459.1 million by 2030. It is expected to expand at a CAGR of 11.07% … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Global CRISPR Market 2022-2028” report has been added to ResearchAndMarkets.com’s offering. The global CRISPR market is anticipated to grow at a substantial CAGR of 36.8 % during the forecast period. Companies Mentioned Addgene AstraZeneca PLC Bio-Rad Laboratories, Inc. Caribou Bioscience Inc. Cellectics SA Crispr Therapeutics AG Editas Medicine, Inc. Genscript Biotech Corp. Horizon … [Read more…]
BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that the Company will host a virtual R&D Day titled “Update on STAR-0215 and Its Clinical Development for the Prevention of HAE Attacks” on September 30th … [Read more…]
− If Approved, Maribavir Would be the First and Only Inhibitor of CMV-specific UL97 Protein Kinase in the EU for Treatment of Adults with Post-transplant CMV Refractory (With or Without Resistance) to Prior Therapies1 − Positive Opinion Based on Phase 3 SOLSTICE Study Demonstrating Maribavir Was Statistically Superior to Conventional Therapies at Study Week 8, … [Read more…]
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$QNCX–Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today detailed highlights from the company’s participation at the Military Health System Research Symposium (MHSRS 2022), which took place September 12 to September 15, 2022, in Kissimmee, Florida. At MHSRS 2022, Quince presented a … [Read more…]
DALLAS–(BUSINESS WIRE)–Generational Equity, a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client, Greenleaf Growers, Inc. to 2900 Madison Ave Holdings, LLC (a holding company of Edible Garden, Inc.). The transaction closed September 2, 2022. Greenleaf Growers, located in Grand Rapids, Michigan, operates as a greenhouse … [Read more…]
— Updated Data from Phase 1 Danon Disease trial expected to include efficacy and safety data from pediatric cohort and longer-term data from adult cohort — — Company to webcast investor event on Sept. 30, at 8:00 a.m. ET — CRANBURY, N.J.–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an … [Read more…]
– Positive Opinion Based on Landmark ZUMA-7 Study in Which 41% of Patients Demonstrated Event-Free Survival at Two Years versus 16% for Standard of Care – SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), today announces that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive … [Read more…]
